Exact Mass: 343.2511

Exact Mass Matches: 343.2511

Found 336 metabolites which its exact mass value is equals to given mass value 343.2511, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

denudatine

(1S,5R,8R,10S,11R,13R,14S,15S,16R)-7-Ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.210,13.01,8.05,16.010,15]nonadecane-11,14-diol

C22H33NO2 (343.2511)


Denudatine is a diterpenoid. It derives from a hydride of an atisane. CID 441729 is a natural product found in Aconitum kusnezoffii and Aconitum carmichaelii with data available.

   

Dibucaine

2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide

C20H29N3O2 (343.226)


A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) D - Dermatologicals > D04 - Antipruritics, incl. antihistamines, anesthetics, etc. > D04A - Antipruritics, incl. antihistamines, anesthetics, etc. > D04AB - Anesthetics for topical use C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics S - Sensory organs > S02 - Otologicals > S02D - Other otologicals > S02DA - Analgesics and anesthetics S - Sensory organs > S01 - Ophthalmologicals > S01H - Local anesthetics > S01HA - Local anesthetics N - Nervous system > N01 - Anesthetics > N01B - Anesthetics, local > N01BB - Amides D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   
   

Atisine

Anthorine

C22H33NO2 (343.2511)


A organic heterohexacyclic compound and diterpene alkaloid isolated from Aconitum anthora. In solution, it is a 2:1 mixture of readily interconvertible epimers at position 20 (the carbon attached to both the nitrogen and an oxygen atom).

   

Cuauchichicine

Veatchine,15-deoxy-16,17-dihydro-15-oxo-, (16-beta,20S)-

C22H33NO2 (343.2511)


   

Garryine

ISOGARRYFOLINE

C22H33NO2 (343.2511)


   

Paravallarine

Paravallarine

C22H33NO2 (343.2511)


A natural product found in Kibatalia laurifolia.

   
   

Piperolein B

(8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one

C21H29NO3 (343.2147)


Minor constituent of Piper nigrum (black pepper). Piperolein B is found in herbs and spices and pepper (spice). Piperolein B is found in herbs and spices. Piperolein B is a minor constituent of Piper nigrum (black pepper

   

Isopiperolein B

(9E)-10-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)dec-9-en-1-one

C21H29NO3 (343.2147)


Isopiperolein B is found in herbs and spices. Isopiperolein B is an alkaloid from the berries of Piper nigrum (pepper). Alkaloid from the berries of Piper nigrum (pepper). Isopiperolein B is found in herbs and spices.

   

8-Methylundecanoylcarnitine

3-[(8-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


8-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methylundecanoylcarnitine

3-[(7-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


7-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methylundecanoylcarnitine

3-[(6-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


6-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methylundecanoylcarnitine

3-[(4-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


4-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methylundecanoylcarnitine

3-[(5-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


5-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Methylundecanoylcarnitine

3-[(10-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


10-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Methylundecanoylcarnitine

3-[(9-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


9-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methylundecanoylcarnitine

3-[(3-methylundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


3-Methylundecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methylundecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methylundecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-3-enoylcarnitine

3-[(2-hydroxyundec-3-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-8-enoylcarnitine

3-[(2-hydroxyundec-8-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-8-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-8-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-8-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-6-enoylcarnitine

3-[(2-hydroxyundec-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-5-enoylcarnitine

3-[(2-hydroxyundec-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E)-2-Hydroxyundec-4-enoylcarnitine

3-[(2-hydroxyundec-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


(4E)-2-Hydroxyundec-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4E)-2-hydroxyundec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E)-2-Hydroxyundec-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E)-2-Hydroxyundec-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-7-enoylcarnitine

3-[(2-hydroxyundec-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-7-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-2-enoylcarnitine

3-[(2-hydroxyundec-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyundec-9-enoylcarnitine

3-[(2-hydroxyundec-9-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


2-Hydroxyundec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyundec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxyundec-9-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxyundec-9-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxoundecanoylcarnitine

3-[(3-oxoundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO5 (343.2359)


3-OxoUndecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxoundecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-OxoUndecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-OxoUndecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Palmitoyl Serine

2-hexadecanamido-3-hydroxypropanoic acid

C19H37NO4 (343.2722)


N-palmitoyl serine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Serine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Aspartic acid

2-tetradecanamidobutanedioic acid

C18H33NO5 (343.2359)


N-myristoyl aspartic acid, also known as N-myristoyl aspartate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Aspartic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Aspartic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Aspartic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Hexadecanoyl-serine

2-METHOXY-5-METHYL-N,N-BIS(1-METHYLETHYL)-GAMMA-PHENYLBENZENEPROPANAMINEFUMARATE

C19H37NO4 (343.2722)


   

(1R,9S,10S)-17-[(3-Hydroxycyclobutyl)methyl]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol

(1R,9S,10S)-17-[(3-Hydroxycyclobutyl)methyl]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol

C21H29NO3 (343.2147)


   

1-(2,6-Dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane

[2-(3,4-dimethoxyphenyl)ethyl][1-(2,6-dimethylphenoxy)propan-2-yl]amine

C21H29NO3 (343.2147)


   

Hydroxyethyl retinamide

N-(2-hydroxyethyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide

C22H33NO2 (343.2511)


   

Sitamaquine

8-(6-Diethylaminohexylamino)-6-methoxy-4-methylquinoline dihydrochloride

C21H33N3O (343.2623)


C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent

   

Bullatine

(5R,11R,14S,15R,16R)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.210,13.01,8.05,16.010,15]nonadecane-11,14-diol

C22H33NO2 (343.2511)


Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses[1]. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed[2]. Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses[1]. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed[2].

   

Broussonetine V

Broussonetine V

C18H33NO5 (343.2359)


   

MONOAMINOILLIMAQUINONE

MONOAMINOILLIMAQUINONE

C21H29NO3 (343.2147)


   

Cyclosmenospongine

Cyclosmenospongine

C21H29NO3 (343.2147)


   

Broussonetine U

Broussonetine U

C18H33NO5 (343.2359)


   

Broussonetine U1

Broussonetine U1

C18H33NO5 (343.2359)


   

(+)-17-Oxocycloprotobuxine

(+)-17-Oxocycloprotobuxine

C23H37NO (343.2875)


   

Daphniyunnine B

Daphniyunnine B

C21H29NO3 (343.2147)


   

Broussonetine O

Broussonetine O

C18H33NO5 (343.2359)


   

Chellespontine

Chellespontine

C22H33NO2 (343.2511)


   
   
   
   
   

Isocuauchichicine

Isocuauchichicine

C22H33NO2 (343.2511)


   

C-Profluorocurine

C-Profluorocurine

C20H27N2O3+ (343.2022)


   

CP-642931

CP-642931

C17H25N7O (343.212)


CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5447; ORIGINAL_PRECURSOR_SCAN_NO 5445 CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5458; ORIGINAL_PRECURSOR_SCAN_NO 5457 CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5487; ORIGINAL_PRECURSOR_SCAN_NO 5486 CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5483; ORIGINAL_PRECURSOR_SCAN_NO 5482 CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5482; ORIGINAL_PRECURSOR_SCAN_NO 5479 CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5493; ORIGINAL_PRECURSOR_SCAN_NO 5492 DATA_PROCESSING MERGING RMBmix ver. 0.2.7; CONFIDENCE standard compound; INTERNAL_ID 292; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5493; ORIGINAL_PRECURSOR_SCAN_NO 5492

   

UNII-575702U55U

UNII-575702U55U

C21H29NO3 (343.2147)


   
   

Hydroxybutorphanol

Hydroxybutorphanol

C21H29NO3 (343.2147)


   

Sitamaquine

Sitamaquine

C21H33N3O (343.2623)


C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent

   

O-dodecanoylcarnitine

O-dodecanoylcarnitine

C19H37NO4 (343.2722)


An O-acylcarnitine having dodecanoyl as the acyl substituent.

   
   

4-methyl-6-(2-benzoyloxypentyl)-quinolizidine

4-methyl-6-(2-benzoyloxypentyl)-quinolizidine

C22H33NO2 (343.2511)


   
   

3beta-Dimethylamino-20-oxo-pregnen-5|3beta-Dimethylamino-5-pregnen-20-on|Dimethylholaphyllamin|Methyl-holaphyllin|Methylholaphyllin

3beta-Dimethylamino-20-oxo-pregnen-5|3beta-Dimethylamino-5-pregnen-20-on|Dimethylholaphyllamin|Methyl-holaphyllin|Methylholaphyllin

C23H37NO (343.2875)


   

piperchabamide F

piperchabamide F

C21H29NO3 (343.2147)


   

(20R)-3beta-Dimethylamino-18,20-oxido-pregnen-5|(20R)-N,N-Dimethyl-3beta-amino-18,20-oxido-Delta5-pregnen|3beta-Dimethylamino-18,20beta-oxido-pregn-5-en

(20R)-3beta-Dimethylamino-18,20-oxido-pregnen-5|(20R)-N,N-Dimethyl-3beta-amino-18,20-oxido-Delta5-pregnen|3beta-Dimethylamino-18,20beta-oxido-pregn-5-en

C23H37NO (343.2875)


   

daphnezomine L

daphnezomine L

C22H33NO2 (343.2511)


   
   

caldaphnidine C

caldaphnidine C

C22H33NO2 (343.2511)


   

N-(4-Hydroxyphenethyl)-2,4-tetradecadienamid

N-(4-Hydroxyphenethyl)-2,4-tetradecadienamid

C22H33NO2 (343.2511)


   

Dimethylholaphyllamine

Dimethylholaphyllamine

C23H37NO (343.2875)


   

daphlongamine B

daphlongamine B

C21H29NO3 (343.2147)


   

(9Z,14Z)-octadeca-9,14-dien-12-ynoic acid piperidine

(9Z,14Z)-octadeca-9,14-dien-12-ynoic acid piperidine

C23H37NO (343.2875)


   

(E)-salignone

(E)-salignone

C23H37NO (343.2875)


   

4-Dihydrofuntumafrine C

4-Dihydrofuntumafrine C

C23H37NO (343.2875)


   

(2E,9Z)-octadeca-2,9-dien-12-ynoic acid piperidine

(2E,9Z)-octadeca-2,9-dien-12-ynoic acid piperidine

C23H37NO (343.2875)


   

(3alpha,5alpha)-3-Aminopregn-16-en-20-one

(3alpha,5alpha)-3-Aminopregn-16-en-20-one

C23H37NO (343.2875)


   

oxo-3 hydroxy-18 methylamino-20(S) pregnadiene-1,4

oxo-3 hydroxy-18 methylamino-20(S) pregnadiene-1,4

C22H33NO2 (343.2511)


   

(3aR)-4t-[trans-2-((2S)-1,6t-dimethyl-piperidin-2r-yl)-vinyl]-3c-methyl-(3ar,4at,8ac)-3a,4,4a,5,6,7,8,8a-octahydro-3H-naphtho[2,3-c]furan-1-one|Himgravin|Himgravine

(3aR)-4t-[trans-2-((2S)-1,6t-dimethyl-piperidin-2r-yl)-vinyl]-3c-methyl-(3ar,4at,8ac)-3a,4,4a,5,6,7,8,8a-octahydro-3H-naphtho[2,3-c]furan-1-one|Himgravin|Himgravine

C22H33NO2 (343.2511)


   

(20S)-20-(methylamino)-3beta-methoxypregn-5,16-diene|salignamine

(20S)-20-(methylamino)-3beta-methoxypregn-5,16-diene|salignamine

C23H37NO (343.2875)


   

N-allylschoberine|N16-allylisoschoberine

N-allylschoberine|N16-allylisoschoberine

C23H25N3 (343.2048)


   

(E,E)-N-(4-Hydroxyphenethyl)-2,4-tetradecadienamide

(E,E)-N-(4-Hydroxyphenethyl)-2,4-tetradecadienamide

C22H33NO2 (343.2511)


   

(E)-2,4-Dimethoxy-3-(gammar,gammar-dimethylallylcinnamoyl)piperidide|2,4-dimethyoxy-3-gamma,gamma-dimethylallyl-trans-cinnamoylpiperidide

(E)-2,4-Dimethoxy-3-(gammar,gammar-dimethylallylcinnamoyl)piperidide|2,4-dimethyoxy-3-gamma,gamma-dimethylallyl-trans-cinnamoylpiperidide

C21H29NO3 (343.2147)


   

calycinumines A

calycinumines A

C21H29NO3 (343.2147)


   

5-epi-smenospongine

5-epi-smenospongine

C21H29NO3 (343.2147)


   
   
   
   
   

Arachidonoyl Cyclopropylamide

N-cyclopropyl-5Z,8Z,11Z,14Z-eicosatetraenamide

C23H37NO (343.2875)


   
   
   
   
   
   
   
   
   
   

Bullatine A

(5R,11R,14S,15R,16R)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.210,13.01,8.05,16.010,15]nonadecane-11,14-diol

C22H33NO2 (343.2511)


Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses[1]. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed[2]. Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses[1]. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed[2].

   

dibucaine

Cinchocaine

C20H29N3O2 (343.226)


D - Dermatologicals > D04 - Antipruritics, incl. antihistamines, anesthetics, etc. > D04A - Antipruritics, incl. antihistamines, anesthetics, etc. > D04AB - Anesthetics for topical use C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics S - Sensory organs > S02 - Otologicals > S02D - Other otologicals > S02DA - Analgesics and anesthetics S - Sensory organs > S01 - Ophthalmologicals > S01H - Local anesthetics > S01HA - Local anesthetics N - Nervous system > N01 - Anesthetics > N01B - Anesthetics, local > N01BB - Amides D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); Flow Injection CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); CONFIDENCE Reference Standard (Level 1) CONFIDENCE standard compound; EAWAG_UCHEM_ID 3294

   

Smenospongine

Smenospongine

C21H29NO3 (343.2147)


   

Lauroylcarnitine

(3R)-3-(dodecanoyloxy)-4-(trimethylazaniumyl)butanoate

C19H37NO4 (343.2722)


Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.

   

(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one

NCGC00180733-02!(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one

C21H29NO3 (343.2147)


   
   

Lauramidopropylbetaine

Lauramidopropylbetaine

[C19H39N2O3]+ (343.2961)


CONFIDENCE standard compound; INTERNAL_ID 2849

   

Putative (3-hydroxyheptadecanoyl)glycine

Putative (3-hydroxyheptadecanoyl)glycine

C19H37NO4 (343.2722)


   

(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one [IIN-based: Match]

NCGC00180733-02!(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one [IIN-based: Match]

C21H29NO3 (343.2147)


   

(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one [IIN-based on: CCMSLIB00000848139]

NCGC00180733-02!(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one [IIN-based on: CCMSLIB00000848139]

C21H29NO3 (343.2147)


   

Lauramidopropyl betaine

Lauramidopropyl betaine

[C19H39N2O3]+ (343.2961)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 15

   

Undecyltyrazolone

Undecyltyrazolone

C21H29NO3 (343.2147)


   

Lauroyl-carnitine; AIF; CE0; CorrDec

Lauroyl-carnitine; AIF; CE0; CorrDec

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; AIF; CE10; CorrDec

Lauroyl-carnitine; AIF; CE10; CorrDec

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; AIF; CE30; CorrDec

Lauroyl-carnitine; AIF; CE30; CorrDec

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; AIF; CE0; MS2Dec

Lauroyl-carnitine; AIF; CE0; MS2Dec

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; AIF; CE10; MS2Dec

Lauroyl-carnitine; AIF; CE10; MS2Dec

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; AIF; CE30; MS2Dec

Lauroyl-carnitine; AIF; CE30; MS2Dec

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; LC-tDDA; CE10

Lauroyl-carnitine; LC-tDDA; CE10

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; LC-tDDA; CE40

Lauroyl-carnitine; LC-tDDA; CE40

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; LC-tDDA; CE20

Lauroyl-carnitine; LC-tDDA; CE20

C19H37NO4 (343.2722)


   

Lauroyl-carnitine; LC-tDDA; CE30

Lauroyl-carnitine; LC-tDDA; CE30

C19H37NO4 (343.2722)


   
   
   
   
   
   
   
   
   
   
   

L-Octanoylcarnitine n-butyl ester

L-Octanoylcarnitine n-butyl ester

C19H37NO4 (343.2722)


   

N-palmitoyl serine

N-hexadecanoyl-serine

C19H37NO4 (343.2722)


   

Piperolein B

(8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one

C21H29NO3 (343.2147)


   

Isopiperolein B

(9E)-10-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)dec-9-en-1-one

C21H29NO3 (343.2147)


   

CAR 12:0

3-(dodecanoyloxy)-4-(trimethylammonio)butanoate;O-lauroylcarnitine;dodecanoylcarnitine;lauroylcarnitine

C19H37NO4 (343.2722)


   

NA 19:1;O3

2-METHOXY-5-METHYL-N,N-BIS(1-METHYLETHYL)-GAMMA-PHENYLBENZENEPROPANAMINEFUMARATE

C19H37NO4 (343.2722)


   

N-(15-methyl-3-hydroxy-hexadecanoyl)-glycine

N-(15-methyl-3-hydroxy-hexadecanoyl)-glycine

C19H37NO4 (343.2722)


   

1-N-(3-INDOLE)ETHYL-4-BOC-AMINOPIPERIDINE

1-N-(3-INDOLE)ETHYL-4-BOC-AMINOPIPERIDINE

C20H29N3O2 (343.226)


   

methyl 2-[[[3-(4-hydroxy-4-methylpentyl)-3-cyclohexen-1-yl]methylene]amino]benzoate

methyl 2-[[[3-(4-hydroxy-4-methylpentyl)-3-cyclohexen-1-yl]methylene]amino]benzoate

C21H29NO3 (343.2147)


   

Terbutaline sulfate

Terbutaline sulfate

C12H19NO3.1/2H2O4S (343.2604)


Terbutaline sulfate is an orally active β2-adrenergic receptor agonist and an active metabolite of bambuterol[1]. Terbutaline sulfate can be used in asthma symptom research[2].

   

NEOCUPROINE HYDROCHLORIDE

NEOCUPROINE HYDROCHLORIDE

C22H33NO2 (343.2511)


   

p-Diethylaminobenzaldehyde-N,N-diphenyl-hydrazone

p-Diethylaminobenzaldehyde-N,N-diphenyl-hydrazone

C23H25N3 (343.2048)


   

TERT-BUTYL 3-((TERT-BUTYLDIMETHYLSILYLOXY)METHYL)-4-OXOPIPERIDINE-1-CARBOXYLATE

TERT-BUTYL 3-((TERT-BUTYLDIMETHYLSILYLOXY)METHYL)-4-OXOPIPERIDINE-1-CARBOXYLATE

C17H33NO4Si (343.2179)


   

(R,R)-N-BENZYL-3,4-TRANS-DIMESOLATEPYRROLIDINE

(R,R)-N-BENZYL-3,4-TRANS-DIMESOLATEPYRROLIDINE

C19H37NO4 (343.2722)


   

leerall / methyl anthranilate schiffs base

leerall / methyl anthranilate schiffs base

C21H29NO3 (343.2147)


   

Fingolimod hydrochloride

Fingolimod hydrochloride

C19H34ClNO2 (343.2278)


D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D000081243 - Sphingosine 1 Phosphate Receptor Modulators C308 - Immunotherapeutic Agent

   

ammonium dodecylbenzenesulphonate

ammonium dodecylbenzenesulphonate

C18H33NO3S (343.2181)


   

p-(Diethylamino)benzaldehyde diphenylhydrazone

p-(Diethylamino)benzaldehyde diphenylhydrazone

C23H25N3 (343.2048)


   

N-(6-aminohexyl)hexane-1,6-diamine,2-(chloromethyl)oxirane,hydrochloride

N-(6-aminohexyl)hexane-1,6-diamine,2-(chloromethyl)oxirane,hydrochloride

C15H35Cl2N3O (343.2157)


   

N-(2-Hydroxyethyl)retinamide

N-(2-Hydroxyethyl)retinamide

C22H33NO2 (343.2511)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

   

N,N,N,N-Tetramethylpararosaniline

N,N,N,N-Tetramethylpararosaniline

C23H25N3 (343.2048)


   
   
   

3-Hydroxybutorphanol

3-Hydroxybutorphanol

C21H29NO3 (343.2147)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   

(1R)-1-(4-((2R,6S)-4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2,6-dimethylpiperazin-1-yl)pyrimidin-2-yl)ethanol

(1R)-1-(4-((2R,6S)-4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2,6-dimethylpiperazin-1-yl)pyrimidin-2-yl)ethanol

C17H25N7O (343.212)


   

3-(Dodecanoylamino)propyl(carboxymethyl)dimethylammonium

3-(Dodecanoylamino)propyl(carboxymethyl)dimethylammonium

C19H39N2O3+ (343.2961)


   

17(R)-HDoHE(1-)

17(R)-HDoHE(1-)

C22H31O3- (343.2273)


A hydroxy polyunsaturated fatty acid anion that is the conjugate base of 17(R)-HDoHE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

3-Oxo-23,24-bisnorchol-4-en-22-oate

3-Oxo-23,24-bisnorchol-4-en-22-oate

C22H31O3- (343.2273)


   

(4Z,7Z,10Z,13Z,16Z,19Z)-22-hydroxydocosahexaenoate

(4Z,7Z,10Z,13Z,16Z,19Z)-22-hydroxydocosahexaenoate

C22H31O3- (343.2273)


A polyunsaturated fatty acid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z,19Z)-22-hydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoate

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoate

C22H31O3- (343.2273)


   

beta-Homovaline-beta-homoalanine-beta-homoleucine

beta-Homovaline-beta-homoalanine-beta-homoleucine

C17H33N3O4 (343.2471)


   

1,2-Dioctanoyl-1-amino-2,3-propanediol

1,2-Dioctanoyl-1-amino-2,3-propanediol

C19H37NO4 (343.2722)


   

(3S)-3-[[(3S)-3-[[(3R)-3-amino-4-methylpentanoyl]amino]butanoyl]amino]-5-methylhexanoic acid

(3S)-3-[[(3S)-3-[[(3R)-3-amino-4-methylpentanoyl]amino]butanoyl]amino]-5-methylhexanoic acid

C17H33N3O4 (343.2471)


   

3-Oxoundecanoylcarnitine

3-Oxoundecanoylcarnitine

C18H33NO5 (343.2359)


   

8-Methylundecanoylcarnitine

8-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

7-Methylundecanoylcarnitine

7-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

6-Methylundecanoylcarnitine

6-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

4-Methylundecanoylcarnitine

4-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

5-Methylundecanoylcarnitine

5-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

9-Methylundecanoylcarnitine

9-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

3-Methylundecanoylcarnitine

3-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

10-Methylundecanoylcarnitine

10-Methylundecanoylcarnitine

C19H37NO4 (343.2722)


   

2-Hydroxyundec-7-enoylcarnitine

2-Hydroxyundec-7-enoylcarnitine

C18H33NO5 (343.2359)


   

2-Hydroxyundec-3-enoylcarnitine

2-Hydroxyundec-3-enoylcarnitine

C18H33NO5 (343.2359)


   

2-Hydroxyundec-8-enoylcarnitine

2-Hydroxyundec-8-enoylcarnitine

C18H33NO5 (343.2359)


   

2-Hydroxyundec-6-enoylcarnitine

2-Hydroxyundec-6-enoylcarnitine

C18H33NO5 (343.2359)


   

2-Hydroxyundec-5-enoylcarnitine

2-Hydroxyundec-5-enoylcarnitine

C18H33NO5 (343.2359)


   

2-Hydroxyundec-2-enoylcarnitine

2-Hydroxyundec-2-enoylcarnitine

C18H33NO5 (343.2359)


   

2-Hydroxyundec-9-enoylcarnitine

2-Hydroxyundec-9-enoylcarnitine

C18H33NO5 (343.2359)


   

(4E)-2-Hydroxyundec-4-enoylcarnitine

(4E)-2-Hydroxyundec-4-enoylcarnitine

C18H33NO5 (343.2359)


   
   
   

N-Methylgitingensine

N-Methylgitingensine

C22H33NO2 (343.2511)


A natural product found in Kibatalia laurifolia.

   
   

(+)-(1R)-1-[4-(4-fluorophenyl)-2,6-diisopropyl-5-propylpyridin-3-yl]ethanol

(+)-(1R)-1-[4-(4-fluorophenyl)-2,6-diisopropyl-5-propylpyridin-3-yl]ethanol

C22H30FNO (343.2311)


   

14-HDoHE(1-)

14-HDoHE(1-)

C22H31O3- (343.2273)


A polyunsaturated hydroxy-fatty acid anion that is the conjugate base of 14-HDoHE, arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   
   

21-HDoHE(1-)

21-HDoHE(1-)

C22H31O3- (343.2273)


An (omega-1)-hydroxy fatty acid anion that is the conjugate base of 21-HDoHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-3-methyl-1-oxopentan-2-yl]carbamic acid tert-butyl ester

N-[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-3-methyl-1-oxopentan-2-yl]carbamic acid tert-butyl ester

C17H33N3O4 (343.2471)


   

(19R,20S)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

(19R,20S)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

C22H31O3- (343.2273)


   

(4Z,7Z,10Z)-12-{3-[(2Z,5Z)-octa-2,5-dien-1-yl]oxiran-2-yl}dodeca-4,7,10-trienoate

(4Z,7Z,10Z)-12-{3-[(2Z,5Z)-octa-2,5-dien-1-yl]oxiran-2-yl}dodeca-4,7,10-trienoate

C22H31O3- (343.2273)


   

(19S,20R)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

(19S,20R)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

C22H31O3- (343.2273)


   

(4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoate

(4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoate

C22H31O3- (343.2273)


   

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoate

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoate

C22H31O3- (343.2273)


   

(4Z,7Z)-9-{3-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]oxiran-2-yl}nona-4,7-dienoate

(4Z,7Z)-9-{3-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]oxiran-2-yl}nona-4,7-dienoate

C22H31O3- (343.2273)


   
   
   
   
   
   

N,N-Dibenzyl-5-phenylpentan-1-amine

N,N-Dibenzyl-5-phenylpentan-1-amine

C25H29N (343.23)


   

N-acyl-6-hydroxysphingosine

N-acyl-6-hydroxysphingosine

C19H37NO4 (343.2722)


   
   
   

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoate

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoate

C22H31O3- (343.2273)


   

7-Hydroxydocosahexaenoate

7-Hydroxydocosahexaenoate

C22H31O3- (343.2273)


   

(2E)-12-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dodec-2-enoate

(2E)-12-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dodec-2-enoate

C18H31O6- (343.2121)


   

(8E,10Z,13Z,16Z,19Z)-7-oxodocosa-8,10,13,16,19-pentaenoate

(8E,10Z,13Z,16Z,19Z)-7-oxodocosa-8,10,13,16,19-pentaenoate

C22H31O3- (343.2273)


   

(7Z,10Z,14E,16Z,19Z)-13-oxodocosa-7,10,14,16,19-pentaenoate

(7Z,10Z,14E,16Z,19Z)-13-oxodocosa-7,10,14,16,19-pentaenoate

C22H31O3- (343.2273)


   

(7Z,10Z,13Z,15E,19Z)-17-oxodocosa-7,10,13,15,19-pentaenoate

(7Z,10Z,13Z,15E,19Z)-17-oxodocosa-7,10,13,15,19-pentaenoate

C22H31O3- (343.2273)


   

(14R)-hydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14R)-hydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O3- (343.2273)


   

(14S)-hydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14S)-hydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O3- (343.2273)


   
   

(E,11R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydodec-2-enoate

(E,11R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydodec-2-enoate

C18H31O6- (343.2121)


   

(7Z,9E,11E)-12-{3-[(2Z,5Z)-octa-2,5-dien-1-yl]oxiran-2-yl}dodeca-7,9,11-trienoate

(7Z,9E,11E)-12-{3-[(2Z,5Z)-octa-2,5-dien-1-yl]oxiran-2-yl}dodeca-7,9,11-trienoate

C22H31O3- (343.2273)


   

(7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-7,10,12,14-tetraenoate

(7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-7,10,12,14-tetraenoate

C22H31O3- (343.2273)


   

N-(3-Hydroxyheptadecanoyl)glycine

N-(3-Hydroxyheptadecanoyl)glycine

C19H37NO4 (343.2722)


   

N-Benzyl-3-menthoxycarbonylpyrrolidine

N-Benzyl-3-menthoxycarbonylpyrrolidine

C22H33NO2 (343.2511)


   

N-Acetylvalylleucylglycine methyl ester

N-Acetylvalylleucylglycine methyl ester

C16H29N3O5 (343.2107)


   

(2S)-2-[1-Hydroxy-4-[(tetrahydro-2H-pyran-2-yl)oxy]butyl]-1-pyrrolidinecarboxylic acid tert-butyl ester

(2S)-2-[1-Hydroxy-4-[(tetrahydro-2H-pyran-2-yl)oxy]butyl]-1-pyrrolidinecarboxylic acid tert-butyl ester

C18H33NO5 (343.2359)


   
   

Veatchine,15-deoxy-16,17-dihydro-15-oxo-, (16-beta,20S)-

Veatchine,15-deoxy-16,17-dihydro-15-oxo-, (16-beta,20S)-

C22H33NO2 (343.2511)


   
   

O-Lauroyl-L-carnitine

O-Lauroyl-L-carnitine

C19H37NO4 (343.2722)


An O-acyl-L-carnitine in which the acyl group is specified as lauroyl (dodecanoyl).

   

N-hexadecanoyl-serine

2-METHOXY-5-METHYL-N,N-BIS(1-METHYLETHYL)-GAMMA-PHENYLBENZENEPROPANAMINEFUMARATE

C19H37NO4 (343.2722)


   

(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoate

(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoate

C22H31O3 (343.2273)


A hydroxy polyunsaturated fatty acid anion that is the conjugate base of 13-HDoHE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoate

(4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

oscr#19(1-)

oscr#19(1-)

C18H31O6 (343.2121)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#19, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(8E,10Z,13Z,16Z,19Z)-7-oxodocosapentaenoate

(8E,10Z,13Z,16Z,19Z)-7-oxodocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (8E,10Z,13Z,16Z,19Z)-7-oxodocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#19(1-)

ascr#19(1-)

C18H31O6 (343.2121)


Conjugate base of ascr#19

   

(7Z,9E,11E,16Z,19Z)-13,14-epoxydocosapentaenoate

(7Z,9E,11E,16Z,19Z)-13,14-epoxydocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (7Z,9E,11E,16Z,19Z)-13,14-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(7Z,10Z,14E,16Z,19Z)-13-oxodocosapentaenoate

(7Z,10Z,14E,16Z,19Z)-13-oxodocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (7Z,10Z,14E,16Z,19Z)-13-oxodocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosahexaenoate

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosahexaenoate

C22H31O3 (343.2273)


A hydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid, arising from deprotonation of the carboxy group; major species at pH 7.3.

   

(16S,17S)-epoxy-(7Z,10Z,12E,14E,19Z)-docosapentaenoate

(16S,17S)-epoxy-(7Z,10Z,12E,14E,19Z)-docosapentaenoate

C22H31O3 (343.2273)


A (4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoate in which the chiral centres at positions 16 and 17 both have S-configuration. An intermediate of specialised proresolving mediators

   

(7Z,10Z,13Z,15E,19Z)-17-oxodocosapentaenoate

(7Z,10Z,13Z,15E,19Z)-17-oxodocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (7Z,10Z,13Z,15E,19Z)-17-oxodocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosahexaenoate

(4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosahexaenoate

C22H31O3 (343.2273)


A hydroxydocosahexaenoate that is the conjugate base of (4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,16Z,19R,20S)-19,20-epoxydocosapentaenoate

(4Z,7Z,10Z,13Z,16Z,19R,20S)-19,20-epoxydocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z,19R,20S)-19,20-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,16Z,19S,20R)-19,20-epoxydocosapentaenoate

(4Z,7Z,10Z,13Z,16Z,19S,20R)-19,20-epoxydocosapentaenoate

C22H31O3 (343.2273)


A polyunsaturated fatty acid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z,19S,20R)-19,20-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoate

(4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosapentaenoate

(4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosapentaenoate

(4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosapentaenoate

C22H31O3 (343.2273)


A docosanoid anion that is the conjugate base of (4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

1-[(9E)-10-(3,4-methylenedioxyphenyl)-9-decenoyl]pyrrolidine

1-[(9E)-10-(3,4-methylenedioxyphenyl)-9-decenoyl]pyrrolidine

C21H29NO3 (343.2147)


A natural product found in Piper boehmeriaefolium.

   

(14R)-HDoHE(1-)

(14R)-HDoHE(1-)

C22H31O3 (343.2273)


A 14-HDoHE(1-) that is the conjugate base of (14R)-HDoHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(14S)-HDoHE(1-)

(14S)-HDoHE(1-)

C22H31O3 (343.2273)


A 14-HDoHE(1-) that is the conjugate base of (14S)-HDoHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   

NA-Cys 15:1(9Z)

NA-Cys 15:1(9Z)

C18H33NO3S (343.2181)


   
   
   
   
   

N-palmitoylserine

(2S)-2-(hexadecanoylamino)-3-hydroxypropanoic acid

C19H37NO4 (343.2722)


-

   

7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-11,14-diol

7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-11,14-diol

C22H33NO2 (343.2511)


   

2-[(1s,2s,4r,6r,7r,10r,11s)-6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde

2-[(1s,2s,4r,6r,7r,10r,11s)-6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde

C22H33NO2 (343.2511)


   

13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-5-one

13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-5-one

C18H33NO5 (343.2359)


   

1-{3-[9-amino-10-(prop-2-en-1-yl)-1-azatricyclo[5.3.1.1²,⁶]dodecan-12-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

1-{3-[9-amino-10-(prop-2-en-1-yl)-1-azatricyclo[5.3.1.1²,⁶]dodecan-12-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

C21H33N3O (343.2623)


   

3-[(1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl)methyl]-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

3-[(1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl)methyl]-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

C21H29NO3 (343.2147)


   

(1s,5r,9s,10s,11s,13r,14r,15s,16s)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-11,14-diol

(1s,5r,9s,10s,11s,13r,14r,15s,16s)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-11,14-diol

C22H33NO2 (343.2511)


   

1-(piperidin-1-yl)octadeca-9,14-dien-12-yn-1-one

1-(piperidin-1-yl)octadeca-9,14-dien-12-yn-1-one

C23H37NO (343.2875)


   

(1s,2r,4s,6s,7s,10r,11r,17s)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

(1s,2r,4s,6s,7s,10r,11r,17s)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

C22H33NO2 (343.2511)


   

(1s,2r,4r,6r,7r,10r,11s,17r)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

(1s,2r,4r,6r,7r,10r,11s,17r)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

C22H33NO2 (343.2511)


   

13-[3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-4-one

13-[3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-4-one

C18H33NO5 (343.2359)


   

(1s,2r,4r,6s,7r,10s,11s,17s)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

(1s,2r,4r,6s,7r,10s,11s,17s)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

C22H33NO2 (343.2511)


   

atisine

NA

C22H33NO2 (343.2511)


{"Ingredient_id": "HBIN017279","Ingredient_name": "atisine","Alias": "NA","Ingredient_formula": "C22H33NO2","Ingredient_Smile": "CC12CCCC3(C1CCC45C3CC(CC4)C(=C)C5O)C6N(C2)CCO6","Ingredient_weight": "343.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT01280","TCMID_id": "1964","TCMSP_id": "NA","TCM_ID_id": "6504;19590;19591;21569","PubChem_id": "135897293","DrugBank_id": "NA"}

   

1-(piperidin-1-yl)octadeca-2,9-dien-12-yn-1-one

1-(piperidin-1-yl)octadeca-2,9-dien-12-yn-1-one

C23H37NO (343.2875)


   

2-[(1s,2s,4s,6r,7s,10r,11r)-6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde

2-[(1s,2s,4s,6r,7s,10r,11r)-6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde

C22H33NO2 (343.2511)


   

(10e)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-5-one

(10e)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-5-one

C18H33NO5 (343.2359)


   

13-[(3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-5-one

13-[(3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-5-one

C18H33NO5 (343.2359)


   

(8s,11s,13e,14s,16s,17s,18r)-13-ethylidene-8,17-dihydroxy-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-11-ium

(8s,11s,13e,14s,16s,17s,18r)-13-ethylidene-8,17-dihydroxy-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-11-ium

[C20H27N2O3]+ (343.2022)


   

(1r,5r,8r,9s,11r,13r,14r,17r,18s,19s)-13,19-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-16-one

(1r,5r,8r,9s,11r,13r,14r,17r,18s,19s)-13,19-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-16-one

C21H29NO3 (343.2147)


   

2-[(1s,2s,4s,6r,7s,10r)-6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde

2-[(1s,2s,4s,6r,7s,10r)-6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde

C22H33NO2 (343.2511)


   

(13z,14s,16r,17r)-13-ethylidene-16,17-dihydroxy-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-11-ium

(13z,14s,16r,17r)-13-ethylidene-16,17-dihydroxy-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-11-ium

[C20H27N2O3]+ (343.2022)


   

(1r,2s,6r,7s,10s,11r,12s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

(1r,2s,6r,7s,10s,11r,12s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

4-(2-hydroxyethyl)-13,17-dimethyl-11-azapentacyclo[12.3.1.0¹,⁵.0⁹,¹⁷.0¹¹,¹⁶]octadec-4-ene-6,18-dione

4-(2-hydroxyethyl)-13,17-dimethyl-11-azapentacyclo[12.3.1.0¹,⁵.0⁹,¹⁷.0¹¹,¹⁶]octadec-4-ene-6,18-dione

C21H29NO3 (343.2147)


   

(1r,2s,4r,6r,7r,10s,11s,12s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

(1r,2s,4r,6r,7r,10s,11s,12s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

11-ethyl-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,16-diol

11-ethyl-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,16-diol

C22H33NO2 (343.2511)


   

(1e,3as,3br,5as,7s,9as,9bs,11as)-7-(dimethylamino)-1-ethylidene-9a,11a-dimethyl-dodecahydro-3h-cyclopenta[a]phenanthren-2-one

(1e,3as,3br,5as,7s,9as,9bs,11as)-7-(dimethylamino)-1-ethylidene-9a,11a-dimethyl-dodecahydro-3h-cyclopenta[a]phenanthren-2-one

C23H37NO (343.2875)


   

7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-one

7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-one

C23H37NO (343.2875)


   

(+/-)-lauroylcarnitine

(+/-)-lauroylcarnitine

C19H37NO4 (343.2722)


   

3-{[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

3-{[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

C21H29NO3 (343.2147)


   

(1s,2r,4r,6r,7r,10r,11s,17s)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

(1s,2r,4r,6r,7r,10r,11s,17s)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

C22H33NO2 (343.2511)


   

(1-{7-methoxy-9a,11a-dimethyl-3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)(methyl)amine

(1-{7-methoxy-9a,11a-dimethyl-3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)(methyl)amine

C23H37NO (343.2875)


   

(2e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-[(2r)-2-methylbutyl]nona-2,8-dienimidic acid

(2e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-[(2r)-2-methylbutyl]nona-2,8-dienimidic acid

C21H29NO3 (343.2147)


   

7,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-4(20)-en-3-one

7,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-4(20)-en-3-one

C21H29NO3 (343.2147)


   

(10e)-13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-5-one

(10e)-13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-5-one

C18H33NO5 (343.2359)


   

(1r,2r,4r,6r,7r,10r,11r,12s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

(1r,2r,4r,6r,7r,10r,11r,12s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

20-(prop-2-en-1-yl)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaene

20-(prop-2-en-1-yl)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaene

C23H25N3 (343.2048)


   

3-{[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

3-{[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

C21H29NO3 (343.2147)


   

9-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one

9-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one

C21H29NO3 (343.2147)


   

3-{[(1r,2s,4ar,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

3-{[(1r,2s,4ar,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

C21H29NO3 (343.2147)


   

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-2,4-dienimidic acid

C22H33NO2 (343.2511)


   

(2r)-1-[(4s,6r,9ar)-6-methyl-octahydro-1h-quinolizin-4-yl]pentan-2-yl benzoate

(2r)-1-[(4s,6r,9ar)-6-methyl-octahydro-1h-quinolizin-4-yl]pentan-2-yl benzoate

C22H33NO2 (343.2511)


   

(10e)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-4-one

(10e)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-4-one

C18H33NO5 (343.2359)


   

(1r,2s,5r,7s,8r,11s,12s,13s)-12-methyl-6-methylidene-14-oxa-17-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹³,¹⁷]docosan-7-ol

(1r,2s,5r,7s,8r,11s,12s,13s)-12-methyl-6-methylidene-14-oxa-17-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹³,¹⁷]docosan-7-ol

C22H33NO2 (343.2511)


   

3-[(2s,3s,8s,11s,12s,15r,16s)-12,16-dimethyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-3-yl]propanoic acid

3-[(2s,3s,8s,11s,12s,15r,16s)-12,16-dimethyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-3-yl]propanoic acid

C22H33NO2 (343.2511)


   

(2-{4,5-dimethoxy-2-[2-(4-methoxyphenyl)ethyl]phenyl}ethyl)dimethylamine

(2-{4,5-dimethoxy-2-[2-(4-methoxyphenyl)ethyl]phenyl}ethyl)dimethylamine

C21H29NO3 (343.2147)


   

2-{6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl}acetaldehyde

2-{6-hydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl}acetaldehyde

C22H33NO2 (343.2511)


   

(2e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylbutyl)nona-2,8-dienimidic acid

(2e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylbutyl)nona-2,8-dienimidic acid

C21H29NO3 (343.2147)


   

(1s,2r,5r,7r,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-ol

(1s,2r,5r,7r,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-ol

C22H33NO2 (343.2511)


   

n-[2-(4-hydroxyphenyl)ethyl]tetradeca-2,4-dienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]tetradeca-2,4-dienimidic acid

C22H33NO2 (343.2511)


   

13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-4-one

13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-4-one

C18H33NO5 (343.2359)


   

(1s,2r,5r,7s,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-ol

(1s,2r,5r,7s,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-ol

C22H33NO2 (343.2511)


   

11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

(1s,2r,5r,7r,8r,11r,12r,18s)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-ol

(1s,2r,5r,7r,8r,11r,12r,18s)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-ol

C22H33NO2 (343.2511)


   

1-[(1r,3as,3bs,7s,9ar,9br,11ar)-7-(dimethylamino)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1r,3as,3bs,7s,9ar,9br,11ar)-7-(dimethylamino)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C23H37NO (343.2875)


   

(1r,2s,4s,6r,7s,10s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

(1r,2s,4s,6r,7s,10s)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylbutyl)nona-2,8-dienimidic acid

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylbutyl)nona-2,8-dienimidic acid

C21H29NO3 (343.2147)


   

(1s,3r,6s,8r,11s,12s,16s)-7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-one

(1s,3r,6s,8r,11s,12s,16s)-7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-one

C23H37NO (343.2875)


   

13-[(3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-4-one

13-[(3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-4-one

C18H33NO5 (343.2359)


   

3-{12,16-dimethyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-3-yl}propanoic acid

3-{12,16-dimethyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-3-yl}propanoic acid

C22H33NO2 (343.2511)


   

12-methyl-6-methylidene-14-oxa-17-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹³,¹⁷]docosan-7-ol

12-methyl-6-methylidene-14-oxa-17-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹³,¹⁷]docosan-7-ol

C22H33NO2 (343.2511)


   

1-{6,9-dihydroxy-6,10-dimethyl-9-phenyl-12-azatricyclo[6.3.1.0⁴,¹²]dodecan-5-yl}ethanone

1-{6,9-dihydroxy-6,10-dimethyl-9-phenyl-12-azatricyclo[6.3.1.0⁴,¹²]dodecan-5-yl}ethanone

C21H29NO3 (343.2147)


   

(10e)-13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-4-one

(10e)-13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridec-10-en-4-one

C18H33NO5 (343.2359)


   

1-[(1s,4s,5s,6r,8s,9s,10r)-6,9-dihydroxy-6,10-dimethyl-9-phenyl-12-azatricyclo[6.3.1.0⁴,¹²]dodecan-5-yl]ethanone

1-[(1s,4s,5s,6r,8s,9s,10r)-6,9-dihydroxy-6,10-dimethyl-9-phenyl-12-azatricyclo[6.3.1.0⁴,¹²]dodecan-5-yl]ethanone

C21H29NO3 (343.2147)


   

3-[(1s,2s,7r,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadeca-3,11-dien-2-yl]propanoic acid

3-[(1s,2s,7r,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadeca-3,11-dien-2-yl]propanoic acid

C22H33NO2 (343.2511)


   

[(1s)-1-[(3as,3br,7s,9ar,9bs,11as)-7-methoxy-9a,11a-dimethyl-3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl](methyl)amine

[(1s)-1-[(3as,3br,7s,9ar,9bs,11as)-7-methoxy-9a,11a-dimethyl-3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl](methyl)amine

C23H37NO (343.2875)


   

3-{[(1s,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

3-{[(1s,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-2-hydroxycyclohexa-2,5-diene-1,4-dione

C21H29NO3 (343.2147)


   

(1s,2r,4r,6s,7r,10s,11s,17r)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

(1s,2r,4r,6s,7r,10s,11s,17r)-11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

C22H33NO2 (343.2511)


   

1-(6-methyl-octahydro-1h-quinolizin-4-yl)pentan-2-yl benzoate

1-(6-methyl-octahydro-1h-quinolizin-4-yl)pentan-2-yl benzoate

C22H33NO2 (343.2511)


   

11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

11-methyl-5-methylidene-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-6-ol

C22H33NO2 (343.2511)


   

13-[3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-5-one

13-[3,4-dihydroxy-5-(hydroxymethyl)-4,5-dihydro-3h-pyrrol-2-yl]-1-hydroxytridecan-5-one

C18H33NO5 (343.2359)


   

(1s,7s,10s,14s,15r,18s,19r)-7,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-4(20)-en-3-one

(1s,7s,10s,14s,15r,18s,19r)-7,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-4(20)-en-3-one

C21H29NO3 (343.2147)


   

(1s,2r,4r,6r,7r,10s,11s,12s)-11-methyl-5-methylidene-14-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

(1s,2r,4r,6r,7r,10s,11s,12s)-11-methyl-5-methylidene-14-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

(1s,9s,13s,14r,16r,17s)-4-(2-hydroxyethyl)-13,17-dimethyl-11-azapentacyclo[12.3.1.0¹,⁵.0⁹,¹⁷.0¹¹,¹⁶]octadec-4-ene-6,18-dione

(1s,9s,13s,14r,16r,17s)-4-(2-hydroxyethyl)-13,17-dimethyl-11-azapentacyclo[12.3.1.0¹,⁵.0⁹,¹⁷.0¹¹,¹⁶]octadec-4-ene-6,18-dione

C21H29NO3 (343.2147)


   

(1s,15r,16s,21r)-20-(prop-2-en-1-yl)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaene

(1s,15r,16s,21r)-20-(prop-2-en-1-yl)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaene

C23H25N3 (343.2048)


   

13,19-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-16-one

13,19-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-16-one

C21H29NO3 (343.2147)


   

10-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)dec-9-en-1-one

10-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)dec-9-en-1-one

C21H29NO3 (343.2147)


   

3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadeca-3,11-dien-2-yl}propanoic acid

3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadeca-3,11-dien-2-yl}propanoic acid

C22H33NO2 (343.2511)


   

(2e,8e,10z)-12-(1,6-dihydropyridin-2-yl)-7-hydroxy-2,6,6,10-tetramethyl-12-oxododeca-2,8,10-trienal

(2e,8e,10z)-12-(1,6-dihydropyridin-2-yl)-7-hydroxy-2,6,6,10-tetramethyl-12-oxododeca-2,8,10-trienal

C21H29NO3 (343.2147)


   

(1s,5r,8r,9r,10s,11r,13r,14s,15s,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-11,14-diol

(1s,5r,8r,9r,10s,11r,13r,14s,15s,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-11,14-diol

C22H33NO2 (343.2511)


   

1-[7-(dimethylamino)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[7-(dimethylamino)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C23H37NO (343.2875)


   

(2e,9z)-1-(piperidin-1-yl)octadeca-2,9-dien-12-yn-1-one

(2e,9z)-1-(piperidin-1-yl)octadeca-2,9-dien-12-yn-1-one

C23H37NO (343.2875)


   

(9z,14z)-1-(piperidin-1-yl)octadeca-9,14-dien-12-yn-1-one

(9z,14z)-1-(piperidin-1-yl)octadeca-9,14-dien-12-yn-1-one

C23H37NO (343.2875)


   

(1r,2r,4r,6r,7r,10s,11s,12r)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

(1r,2r,4r,6r,7r,10s,11s,12r)-11-methyl-5-methylidene-13-oxa-16-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹²,¹⁶]docosan-6-ol

C22H33NO2 (343.2511)


   

3-{[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-4-hydroxycyclohexa-3,5-diene-1,2-dione

3-{[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-amino-4-hydroxycyclohexa-3,5-diene-1,2-dione

C21H29NO3 (343.2147)


   

3-[(1r,2r,7s,10r,13r,14s)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadeca-3,11-dien-2-yl]propanoic acid

3-[(1r,2r,7s,10r,13r,14s)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadeca-3,11-dien-2-yl]propanoic acid

C22H33NO2 (343.2511)


   

3-[(1s,2r,7r,10s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadec-12-en-2-yl]propanoic acid

3-[(1s,2r,7r,10s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadec-12-en-2-yl]propanoic acid

C22H33NO2 (343.2511)


   

(1z,3as,3br,5as,7s,9as,9bs,11as)-7-(dimethylamino)-1-ethylidene-9a,11a-dimethyl-dodecahydro-3h-cyclopenta[a]phenanthren-2-one

(1z,3as,3br,5as,7s,9as,9bs,11as)-7-(dimethylamino)-1-ethylidene-9a,11a-dimethyl-dodecahydro-3h-cyclopenta[a]phenanthren-2-one

C23H37NO (343.2875)